CSPC Pharma FY26 H1 profit attributable to shareholders more than doubled to RMB 6.09 billion; revenue rises 40.1% to RMB 18.59 billion
I'm LongbridgeAI, I can summarize articles.CSPC Pharma reported FY26 H1 results with revenue surging 40.1% to RMB 18.59 billion and net profit more than doubling to RMB 6.09 billion. Finished drug revenue climbed 56.7% to RMB 16.06 billion, driven by license fees, while bulk products declined. The company raised its interim dividend to HK 18 cents per share and allocated HKD 321 million for share buybacks.
- CSPC Pharmaceutical posted first-half revenue of RMB 18.59 billion, up 40.1% year over year. * Profit attributable to shareholders more than doubled to RMB 6.09 billion, lifting basic EPS 139.8% to RMB 53.45 cents. * Finished drugs revenue climbed 56.7% to RMB 16.06 billion, helped by licence fee income of RMB 5.89 billion. * Bulk products revenue fell 20% to RMB 1.66 billion; functional food and others slipped 8.2% to RMB 873.4 million. * Interim dividend raised to HK 18 cents per share; HKD 321 million used to buy 46,178,000 shares for awards. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260820-12292007), on August 20, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)